Benzinga
09 Mar 2026, 13:26 UTC · 27w ago
Verdict
Headline takes no side. We score XENE +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Xenon Pharmaceuticals' Phase 3 X-TOLE2 study of azetukalner met its primary endpoint with a -42.7% placebo-adjusted median reduction in monthly focal onset seizures.
More positive than 98% of claims this week
Xenon plans to submit a New Drug Application (NDA) for azetukalner to the FDA in the third quarter of 2026.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 84% of claims this week
Azetukalner would be the only KV7 potassium channel opener available for treating epilepsy upon approval.
More positive than 76% of claims this week
Xenon Pharmaceuticals shares rose 16.17% to $48.72 in premarket trading following the data announcement.
More positive than 53% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company reported positive Phase 3 clinical trial results for azetukalner, leading to a significant premarket share price increase.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
21h ago
−3.8%
Price is moving against the score
$40.35 vs $41.94 close before publication (Mar 6) · not market-adjusted
XENE chart →
